Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04178174
PHASE3

Stereotactic Boost and Short-course Radiation Therapy for Oropharynx Cancer

Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)

View on ClinicalTrials.gov

Summary

This is a randomized clinical trial comparing the outcomes of short-course chemoradiation consisting in stereotactic boost to the gross tumor and de-esclalated chemoradiation to the elective neck in human papilloma associated oropharynx cancer vs. the current standard 7-week course chemoradiation.

Official title: Stereotactic Boost and SHOrt-course Radiation Therapy for HPV-associated OroPharynx Cancer Trial: A Randomized Multicentric Phase III Trial

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

360

Start Date

2020-02-23

Completion Date

2029-12

Last Updated

2025-05-18

Healthy Volunteers

No

Interventions

RADIATION

SABR boost and de-escalated chemoradiation

Stereotactic body radiotherapy boost to the gross tumor volume to a dose of 14 Gy in 2 fractions, followed by cisplatin-based chemoradiation to a dose of 40 Gy in 20 fractions

RADIATION

Standard chemoradiation

Standard Cisplatin-based chemoradiation to a dose of 70 Gy in 33 fractions

Locations (2)

London Health Sciences Center

London, Ontario, Canada

Centre Hospitalier de l'Université de Montréal

Montreal, Quebec, Canada